16.27

0.37% 0.06

Pre-market: 16.21 -0.06 -0.37%

Acadia Pharmaceuticals Inc (ACAD)

Overview News Price History Option Chain Financials Why ACAD Down? Discussions Forecast

Acadia Pharmaceuticals Inc stock is traded at $16.27, with a volume of 1.06M. It is up +0.37% in the last 24 hours and up +6.34% over the past month. Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Previous Close:

$16.21

Open:

$16.25

24h Volume:

1.06M

Relative Volume:

0.81

Market Cap:

$2.71B

Revenue:

$890.53M

Net Income/Loss:

$30.57M

P/E Ratio:

-17.68

EPS:

-0.92

Net Cash Flow:

$80.53M

1W Performance:

-7.50%

1M Performance:

+6.34%

6M Performance:

+7.75%

1Y Performance:

-29.01%

1-Day Range:

$16.05

$16.39

1-Week Range:

$16.05

$17.77

52-Week Range:

$14.15

$32.59

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name

Acadia Pharmaceuticals Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

858-558-2871

Address

12830 EL CAMINO REAL, SAN DIEGO

Employee

620

Twitter

@acadiapharma

Next Earnings Date

2024-11-06

Latest SEC Filings

ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACAD	16.27	2.71B	890.53M	30.57M	80.53M	-0.92
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-24	Downgrade	Mizuho	Buy → Neutral
Mar-12-24	Reiterated	Needham	Buy
Jan-30-24	Initiated	Robert W. Baird	Outperform
Jan-24-24	Upgrade	Needham	Hold → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-13-23	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-06-23	Upgrade	Mizuho	Neutral → Buy
Oct-17-23	Initiated	UBS	Buy
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-04-22	Downgrade	Goldman	Neutral → Sell
Nov-01-22	Initiated	Loop Capital	Hold
Aug-08-22	Downgrade	Citigroup	Buy → Neutral
Aug-05-22	Downgrade	Citigroup	Buy → Neutral
Jun-21-22	Downgrade	Jefferies	Buy → Underperform
Jun-16-22	Upgrade	Jefferies	Hold → Buy
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-05-22	Upgrade	Citigroup	Neutral → Buy
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold
Apr-06-21	Downgrade	Goldman	Buy → Neutral
Apr-06-21	Downgrade	Jefferies	Buy → Hold
Apr-06-21	Downgrade	Mizuho	Buy → Neutral
Apr-05-21	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-10-21	Downgrade	BofA Securities	Buy → Neutral
Mar-09-21	Downgrade	Citigroup	Buy → Neutral
Mar-09-21	Downgrade	Guggenheim	Buy → Neutral
Mar-09-21	Reiterated	H.C. Wainwright	Buy
Mar-09-21	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-21	Downgrade	Stifel	Buy → Hold
Dec-16-20	Initiated	Mizuho	Buy
Nov-16-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Initiated	Morgan Stanley	Overweight
Jul-07-20	Upgrade	Stifel	Hold → Buy
Apr-16-20	Initiated	Jefferies	Buy
Mar-31-20	Upgrade	Goldman	Neutral → Buy
Mar-06-20	Initiated	Citigroup	Buy
Dec-16-19	Initiated	Guggenheim	Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-01-19	Initiated	RBC Capital Mkts	Outperform
Sep-13-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-10-19	Upgrade	Canaccord Genuity	Hold → Buy
Jul-23-19	Reiterated	Needham	Buy
Dec-10-18	Initiated	Canaccord Genuity	Hold
Sep-21-18	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-09-18	Reiterated	Stifel	Hold
Aug-07-18	Initiated	Stifel	Hold
Aug-06-18	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

06:12 AM

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

06:12 AM

03:18 AM

When (ACAD) Moves Investors should Listen - Stock Traders Daily

03:18 AM

Nov 20, 2024

Acadia Pharmaceuticals announces executive shakeup - Investing.com

Nov 20, 2024

Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause - MarketWatch

Nov 20, 2024

Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure - TipRanks

Nov 20, 2024

Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause - StreetInsider.com

Nov 20, 2024

Acadia Pharma ticks lower amid Deutsche Bank downgrade after surge on patent win - MSN

Nov 20, 2024

Acadia Pharmaceuticals CFO sells shares worth $172,453 By Investing.com - Investing.com Canada

Nov 19, 2024

Acadia Pharmaceuticals' COO sells $173,630 in stock By Investing.com - Investing.com Canada

Nov 19, 2024

FY2024 Earnings Estimate for ACAD Issued By Leerink Partnrs - MarketBeat

Nov 19, 2024

Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat

Nov 16, 2024

Nov 15, 2024

Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan

Nov 15, 2024

Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada

Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com

Nov 13, 2024

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat

Nov 13, 2024

Nov 12, 2024

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance

Nov 12, 2024

US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha

Nov 11, 2024

What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat

Nov 11, 2024

FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat

Nov 11, 2024

Nov 10, 2024

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN

Nov 10, 2024

Nov 09, 2024

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq

Nov 08, 2024

Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks

Nov 08, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat

Nov 08, 2024

HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat

Nov 08, 2024

ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St

Nov 08, 2024

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024